Vetter, a global Contract Development and Manufacturing Organization (CDMO) is helping partners to address challenges and for complex fill and finish solutions by offering comprehensive manufacturing services for clinical trials and supporting customer products path to commercialization. The company’s Skokie facility has helped to bring five new customer products to market since it began full operations in 2011, with another four expected to launch in the next few months.
 

Currently, Vetter Development Service runs more than 80 projects in phase I and II clinical development. Over the past few years, the facility executed more than 30 transfers from its early clinical projects to Germany for further late-stage development. 
 
“Our clinical manufacturing sites are an essential part of Vetter’s commercial business pipeline. And the Skokie site has demonstrated an impressive track record of success since its opening twelve years ago. In the last year alone, we have acquired more than 10 new customers and their promising molecules,” said Dr. Claus Feussner, Senior Vice President Vetter Development Service. 
 
“Overall, our ongoing investments in clinical filling capabilities are proof of Vetter’s consistent strategic approach to keeping abreast of the market and our focus on the important drug development needs of our customers,” added Carsten Press, Senior Vice President Key Account Management, Supply Chain Management and Marketing at Vetter.
 
Next to Vetter Development Services US, the company’s newest clinical manufacturing site in Rankweil, Austria has increased the company’s capacity in the field of process development as well as clinical manufacturing of Phase I and II injectables for customers. Purchased in 2020, the facility received its manufacturing authorization in late 2021 and successfully completed its first customer fills early last year. Vetter Development Services Austria acts as a European counterpart to Skokie, helping to expand the company’s international presence and increase capacity.